Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 19, 2008
GSK is going after Genentech's (Herceptin) Cookies....
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.
June 19, 2008
Melanoma: The Holy Grail at Last??
Analysis of: Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
Author: GLG Expert Contributor
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
June 11, 2008
Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
Analysis of: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
June 9, 2008
Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
June 6, 2008
Transgene's TG4010 Vaccine for Lung Ca - Add it to the List...
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Transgene's TG4010 vaccine has a fairy elegant two-gene design.  It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer.  More mature survival data will be ready by year's end.  Phase III study is being planned.  ...
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 4, 2008
Antisoma's ASA404: Another Anti-Angiogenesis Agent to Watch
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research.  The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective. 
June 3, 2008
Genentech’s Avastin Appears Safe in Early Colon Cancer
Analysis of: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. | www.abstract.asco.org
Author: GLG Expert Contributor
While chemo plus Avastin is the standard of care for first treatment of advanced colon cancer, chemotherapy alone is used for most early colon cancer. This large study demonstrates the relative safety of adding Avastin to chemo in the early - adjuvant – setting.
June 3, 2008
Continuing Genentech's Herceptin - Confirming What We Suspected
Analysis of: Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Many of us oncologists have been in the practice of continuing  Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug.  Now, this randomized study gives data to back up that practice.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 414

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics